Stock Track | CVS Health Soars 5% as Aetna Turnaround Boosts 2025 Outlook

Stock Track

02-14

CVS Health Corp. (NYSE: CVS) stock surged over 5% in pre-market trading on Thursday as the healthcare giant provided an upbeat outlook for 2025, driven by the expected recovery in its Aetna health insurance business.

The company reported mixed results for the fourth quarter of 2024, with revenue of $97.71 billion beating estimates but adjusted earnings per share (EPS) of $1.19 falling short due to continued pressure in the Healthcare Benefits segment. However, CVS Health expressed confidence in its future performance, forecasting 2025 adjusted EPS of $5.75 to $6.00, which represents a significant improvement over the previous year.

The key driver behind this optimism is the anticipated turnaround in Aetna's operations, particularly in the lucrative Medicare Advantage market. CVS Health's new CEO, David Joyner, highlighted the company's "deliberate approach" to Medicare Advantage bids and improved star ratings, which are expected to boost margins in this segment.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1182521383"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182521383\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1182521383?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-14 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182521383","market":"us","top_or_hot":-1,"title":"Stock Track | CVS Health Soars 5% as Aetna Turnaround Boosts 2025 Outlook","media":"Stock Track","content":"<p>CVS Health Corp. (NYSE: CVS) stock surged over 5% in pre-market trading on Thursday as the healthcare giant provided an upbeat outlook for 2025, driven by the expected recovery in its Aetna health insurance business.</p>\n\n<p>The company reported mixed results for the fourth quarter of 2024, with revenue of $97.71 billion beating estimates but adjusted earnings per share (EPS) of $1.19 falling short due to continued pressure in the Healthcare Benefits segment. However, CVS Health expressed confidence in its future performance, forecasting 2025 adjusted EPS of $5.75 to $6.00, which represents a significant improvement over the previous year.</p>\n\n<p>The key driver behind this optimism is the anticipated turnaround in Aetna's operations, particularly in the lucrative Medicare Advantage market. CVS Health's new CEO, David Joyner, highlighted the company's \"deliberate approach\" to Medicare Advantage bids and improved star ratings, which are expected to boost margins in this segment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CVS Health Soars 5% as Aetna Turnaround Boosts 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CVS Health Soars 5% as Aetna Turnaround Boosts 2025 Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-14 02:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CVS Health Corp. (NYSE: CVS) stock surged over 5% in pre-market trading on Thursday as the healthcare giant provided an upbeat outlook for 2025, driven by the expected recovery in its Aetna health insurance business.</p>\n\n<p>The company reported mixed results for the fourth quarter of 2024, with revenue of $97.71 billion beating estimates but adjusted earnings per share (EPS) of $1.19 falling short due to continued pressure in the Healthcare Benefits segment. However, CVS Health expressed confidence in its future performance, forecasting 2025 adjusted EPS of $5.75 to $6.00, which represents a significant improvement over the previous year.</p>\n\n<p>The key driver behind this optimism is the anticipated turnaround in Aetna's operations, particularly in the lucrative Medicare Advantage market. CVS Health's new CEO, David Joyner, highlighted the company's \"deliberate approach\" to Medicare Advantage bids and improved star ratings, which are expected to boost margins in this segment.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVS","symbol_name":"西維斯健康","start_time":0,"source_url":"","article_id":"1182521383","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182521383","pubTimestamp":1739471377,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CVS Health Corp.  stock surged over 5% in pre-market trading on Thursday as the healthcare giant provided an upbeat outlook for 2025, driven by the expected recovery in its Aetna health insurance business.The company reported mixed results for the fourth quarter of 2024, with revenue of $97.71 billion beating estimates but adjusted earnings per share  of $1.19 falling short due to continued pressure in the Healthcare Benefits segment. However, CVS Health expressed confidence in its future perfor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVS":"西维斯健康"},"translate_title":"Aetna扭亏为盈提振2025年前景，股票跟踪CVS Health飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"CVS Health Corp. (NYSE: CVS) stock surged over 5% in pre-market trading on Thursday as the healthcare giant provided an upbeat outlook for 2025, driven by the expected recovery in its Aetna health insurance business.\nThe company reported mixed results for the fourth quarter of 2024, with revenue of $97.71 billion beating estimates but adjusted earnings per share (EPS) of $1.19 falling short due to continued pressure in the Healthcare Benefits segment. However, CVS Health expressed confidence in its future performance, forecasting 2025 adjusted EPS of $5.75 to $6.00, which represents a significant improvement over the previous year.\nThe key driver behind this optimism is the anticipated turnaround in Aetna's operations, particularly in the lucrative Medicare Advantage market. CVS Health's new CEO, David Joyner, highlighted the company's \"deliberate approach\" to Medicare Advantage bids and improved star ratings, which are expected to boost margins in this segment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}